Gregory L Sahlem1, Nathaniel L Baker2, Mark S George1,3, Robert J Malcolm1, Aimee L McRae-Clark1. 1. a Department of Psychiatry , Medical University of South Carolina , Charleston , SC , USA. 2. b Department of Public Health Sciences , Medical University of South Carolina , Charleston , SC , USA. 3. c Department of Psychiatry, Ralph H. Johnson Veterans Administration Hospital , Charleston , SC , USA.
Abstract
BACKGROUND: Cannabis use disorder (CUD) is a common condition with few treatments. Several studies in other substance use disorders have found that applying repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC) decreases cue-elicited craving and possibly decreases use. To date, there have been no studies attempting to use rTMS in CUD. OBJECTIVES: This study was conducted to determine if rTMS could be feasibly delivered to a group of non-treatment seeking CUD participants. Secondarily, the study aimed to estimate the effect of rTMS on craving. METHODS: In a double-blind, sham-controlled, crossover design, a single session of active or sham rTMS (Left DLPFC, 10 Hz, 110% rMT, 4000 pulses) was delivered during a validated cannabis cue paradigm. Participants crossed over to complete the other condition one week later. The feasibility and tolerability were measured by the rate of retention, and the percentage of participants able to tolerate full dose rTMS, respectively. Craving was measured using the Marijuana Craving Questionnaire (MCQ). RESULTS:Eighteen non-treatment seeking CUD participants were recruited from the community; 16 (three women) completed the trial (89% retained for the three study visits). All of the treatment completers tolerated rTMS at full dose without adverse effects. There was not a significant reduction in the total MCQ when participants received active rTMS as compared to sham rTMS. CONCLUSION:rTMS can be safely and feasibly delivered to CUD participants, and treatment is well tolerated. A single session of rTMS applied to the DLPFC may not reduce cue-elicited craving in heavy cannabis users.
RCT Entities:
BACKGROUND:Cannabis use disorder (CUD) is a common condition with few treatments. Several studies in other substance use disorders have found that applying repetitive transcranial magnetic stimulation (rTMS) to the dorsolateral prefrontal cortex (DLPFC) decreases cue-elicited craving and possibly decreases use. To date, there have been no studies attempting to use rTMS in CUD. OBJECTIVES: This study was conducted to determine if rTMS could be feasibly delivered to a group of non-treatment seeking CUDparticipants. Secondarily, the study aimed to estimate the effect of rTMS on craving. METHODS: In a double-blind, sham-controlled, crossover design, a single session of active or sham rTMS (Left DLPFC, 10 Hz, 110% rMT, 4000 pulses) was delivered during a validated cannabis cue paradigm. Participants crossed over to complete the other condition one week later. The feasibility and tolerability were measured by the rate of retention, and the percentage of participants able to tolerate full dose rTMS, respectively. Craving was measured using the Marijuana Craving Questionnaire (MCQ). RESULTS: Eighteen non-treatment seeking CUDparticipants were recruited from the community; 16 (three women) completed the trial (89% retained for the three study visits). All of the treatment completers tolerated rTMS at full dose without adverse effects. There was not a significant reduction in the total MCQ when participants received active rTMS as compared to sham rTMS. CONCLUSION: rTMS can be safely and feasibly delivered to CUDparticipants, and treatment is well tolerated. A single session of rTMS applied to the DLPFC may not reduce cue-elicited craving in heavy cannabis users.
Entities:
Keywords:
Cannabis; TMS; craving; marijuana; transcranial magnetic stimulation
Authors: Xingbao Li; Robert J Malcolm; Kristina Huebner; Colleen A Hanlon; Joseph J Taylor; Kathleen T Brady; Mark S George; Ronald E See Journal: Drug Alcohol Depend Date: 2013-08-26 Impact factor: 4.492
Authors: Victoria C Wing; Mera S Barr; Caroline E Wass; Nir Lipsman; Andres M Lozano; Zafiris J Daskalakis; Tony P George Journal: Brain Stimul Date: 2012-07-09 Impact factor: 8.955
Authors: Aimee L McRae-Clark; Rickey E Carter; Kimber L Price; Nathaniel L Baker; Suzanne Thomas; Michael E Saladin; Kathleen Giarla; Katherine Nicholas; Kathleen T Brady Journal: Psychopharmacology (Berl) Date: 2011-06-28 Impact factor: 4.530
Authors: Colleen A Hanlon; Logan T Dowdle; Christopher W Austelle; William DeVries; Oliver Mithoefer; Bashar W Badran; Mark S George Journal: Brain Res Date: 2015-03-11 Impact factor: 3.252
Authors: William M McDonald; Valerie Durkalski; Edward R Ball; Paul E Holtzheimer; Martina Pavlicova; Sarah H Lisanby; David Avery; Berry S Anderson; Ziad Nahas; Paul Zarkowski; Harold A Sackeim; Mark S George Journal: Depress Anxiety Date: 2011-09-02 Impact factor: 6.505
Authors: Nora D Volkow; Joanna S Fowler; Gene-Jack Wang; Frank Telang; Jean Logan; Millard Jayne; Yeming Ma; Kith Pradhan; Christopher Wong; James M Swanson Journal: Neuroimage Date: 2009-11-11 Impact factor: 6.556
Authors: Gregory L Sahlem; Margaret A Caruso; E Baron Short; James B Fox; Brian J Sherman; Andrew J Manett; Robert J Malcolm; Mark S George; Aimee L McRae-Clark Journal: Brain Stimul Date: 2019-09-30 Impact factor: 8.955
Authors: Hamed Ekhtiari; Hosna Tavakoli; Giovanni Addolorato; Chris Baeken; Antonello Bonci; Salvatore Campanella; Luis Castelo-Branco; Gaëlle Challet-Bouju; Vincent P Clark; Eric Claus; Pinhas N Dannon; Alessandra Del Felice; Tess den Uyl; Marco Diana; Massimo di Giannantonio; John R Fedota; Paul Fitzgerald; Luigi Gallimberti; Marie Grall-Bronnec; Sarah C Herremans; Martin J Herrmann; Asif Jamil; Eman Khedr; Christos Kouimtsidis; Karolina Kozak; Evgeny Krupitsky; Claus Lamm; William V Lechner; Graziella Madeo; Nastaran Malmir; Giovanni Martinotti; William M McDonald; Chiara Montemitro; Ester M Nakamura-Palacios; Mohammad Nasehi; Xavier Noël; Masoud Nosratabadi; Martin Paulus; Mauro Pettorruso; Basant Pradhan; Samir K Praharaj; Haley Rafferty; Gregory Sahlem; Betty Jo Salmeron; Anne Sauvaget; Renée S Schluter; Carmen Sergiou; Alireza Shahbabaie; Christine Sheffer; Primavera A Spagnolo; Vaughn R Steele; Ti-Fei Yuan; Josanne D M van Dongen; Vincent Van Waes; Ganesan Venkatasubramanian; Antonio Verdejo-García; Ilse Verveer; Justine W Welsh; Michael J Wesley; Katie Witkiewitz; Fatemeh Yavari; Mohammad-Reza Zarrindast; Laurie Zawertailo; Xiaochu Zhang; Yoon-Hee Cha; Tony P George; Flavio Frohlich; Anna E Goudriaan; Shirley Fecteau; Stacey B Daughters; Elliot A Stein; Felipe Fregni; Michael A Nitsche; Abraham Zangen; Marom Bikson; Colleen A Hanlon Journal: Neurosci Biobehav Rev Date: 2019-07-02 Impact factor: 8.989
Authors: Aurélia Gay; Julien Cabe; Ingrid De Chazeron; Céline Lambert; Maxime Defour; Vikesh Bhoowabul; Thomas Charpeaud; Aurore Tremey; Pierre-Michel Llorca; Bruno Pereira; Georges Brousse Journal: J Clin Med Date: 2022-01-26 Impact factor: 4.241
Authors: Karolina Kozak Bidzinski; Darby J E Lowe; Marcos Sanches; Maryam Sorkhou; Isabelle Boileau; Michael Kiang; Daniel M Blumberger; Gary Remington; Clement Ma; David J Castle; Rachel A Rabin; Tony P George Journal: Schizophrenia (Heidelb) Date: 2022-02-24